Selecta licenses Xork IgG protease to Astellas for up to $340M plus royalties for Pompe disease

Cartesian Therapeutics, Inc.

Licenses Xork to Astellas for $10M upfront, up to $340M in milestones plus royalties on sales for Pompe disease.
Phase 3 DISSOLVE I & II topline data for SEL-212 in chronic refractory gout expected in Q1 2023.
Selected IL-2 development candidate to combine with ImmTOR for autoimmune diseases; IND-enabling studies planned in 2023.
Initiated Phase 1/2 ReiMMAgine trial of SEL-302 (AAV gene therapy + ImmTOR) for methylmalonic acidemia.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Göran A. Ando

Director

RNAC · Cartesian Therapeutics, Inc.

Effective: 2023-01-04
Filed: January 9, 2023, 6:59 PM ET

On January 4, 2023, Göran A. Ando, M.D., a member of the Board of Directors (the “Board”) of Selecta Biosciences, Inc. (the “Company”), notified the Company that he is retiring from the Company’s Board effective immediately.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Göran A. Ando retired as Director at Cartesian Therapeutics, Inc..

Action: retired
Role: Director

Exact text from the filing

On January 4, 2023, Göran A. Ando, M.D., a member of the Board of Directors (the “Board”) of Selecta Biosciences, Inc. (the “Company”), notified the Company that he is retiring from the Company’s Board effective immediately.

View on SEC.gov

Cartesian Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001453687-23-000037

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.